Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30105% above fair value
$3.99−0.07 (-1.72%)
Close on Nov 13, 2026Market cap $1.40BP/E –Yield –
Nuvation Bio profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Nuvation Bio's profit margin for the twelve months ending Sep 30, 2026 was -67.4%. For fiscal 2025 it was -325.3%, against -7213.8% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -325.3% | +6888.4 |
| FY2024 | Dec 31, 2024 | -7213.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -93.2% | +332.0 |
| Q2 FY2026 | Jun 30, 2026 | -198.3% | +1022.6 |
| Q1 FY2026 | Mar 31, 2026 | 6.5% | +1732.7 |
| Q4 FY2025 | Dec 31, 2025 | -87.4% | +778.4 |
| Q3 FY2025 | Sep 30, 2025 | -425.2% | +5243.3 |
| Q2 FY2025 | Jun 30, 2025 | -1220.9% | +31008.5 |
| Q1 FY2025 | Mar 31, 2025 | -1726.2% | – |
| Q4 FY2024 | Dec 31, 2024 | -865.8% | – |
| Q3 FY2024 | Sep 30, 2024 | -5668.5% | – |
| Q2 FY2024 | Jun 30, 2024 | -32229.4% | – |
See a number that looks wrong?